Filings
| Filing | Date | Type | Filed with |
|---|
| Chair and Deputy Chair Appointments | Nov 5, 2026 | Management or board change | ASX |
|---|
| Results of 2026 Annual General Meeting | Nov 5, 2026 | Meeting outcome | ASX |
|---|
| AGM Chair address and CEO presentation | Nov 5, 2026 | Meeting outcome | ASX |
|---|
| Becoming a substantial holder | Nov 2, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - SPL | Oct 29, 2026 | Financing | ASX |
|---|
| Details of Company Address | Oct 23, 2026 | Other filings | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 21, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 21, 2026 | Quarterly report | ASX |
|---|
| $3.5 Million R&D Tax Incentive Received | Oct 21, 2026 | Other filings | ASX |
|---|
| Starpharma Investor Presentation Petalion Webinar | Oct 20, 2026 | Operations update | ASX |
|---|
| Starpharma secures majority ownership of Petalion | Oct 19, 2026 | Acquisition or disposal | ASX |
|---|
| Starpharma secures majority ownership of Petalion | Oct 19, 2026 | Acquisition or disposal | ASX |
|---|
| Trading Halt | Oct 15, 2026 | Trading halt or suspension | ASX |
|---|
| Change in substantial holding | Oct 7, 2026 | Ownership change notice | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 5, 2026 | Meeting notice | ASX |
|---|
| Change of Director's Interest Notice - C Maley | Oct 4, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - SPL | Oct 4, 2026 | Financing | ASX |
|---|
| Notification of cessation of securities - SPL | Oct 4, 2026 | Financing | ASX |
|---|
| Chair and Deputy Chair Appointments | Sep 30, 2026 | Management or board change | ASX |
|---|
| Ceasing to be a substantial holder | Sep 25, 2026 | Ownership change notice | ASX |
|---|
| Becoming a substantial holder | Sep 22, 2026 | Ownership change notice | ASX |
|---|
| Ceasing to be a substantial holder | Sep 15, 2026 | Ownership change notice | ASX |
|---|
| Annual General Meeting 2026 Date | Sep 15, 2026 | Meeting notice | ASX |
|---|
| Becoming a substantial holder | Sep 11, 2026 | Ownership change notice | ASX |
|---|
| S&P DJI Announces September 2026 Quarterly Rebalance | Sep 4, 2026 | Other filings | ASX |
|---|
| Ceasing to be a substantial holder | Aug 31, 2026 | Ownership change notice | ASX |
|---|
| FY26 Key Financial Results and Annual Report | Aug 25, 2026 | Annual report | ASX |
|---|
| 2026 Appendix 4G and Corporate Governance Statement | Aug 25, 2026 | Other filings | ASX |
|---|
| 2026 Annual Report | Aug 25, 2026 | Annual report | ASX |
|---|
| Preliminary Final Report | Aug 25, 2026 | Results | ASX |
|---|
| Becoming a substantial holder | Aug 24, 2026 | Ownership change notice | ASX |
|---|
| Ceasing to be a substantial holder | Aug 19, 2026 | Ownership change notice | ASX |
|---|
| Change in substantial holding | Aug 18, 2026 | Ownership change notice | ASX |
|---|
| Change in substantial holding | Aug 13, 2026 | Ownership change notice | ASX |
|---|
| Change of Director Interest Notice - R Basser | Aug 12, 2026 | Management or board change | ASX |
|---|
| Change of Director Interest Notice - R Thomas | Aug 12, 2026 | Management or board change | ASX |
|---|
| Change of Director Interest Notice - L Cheng | Aug 12, 2026 | Management or board change | ASX |
|---|
| Change of Director Interest Notice - J Davies | Aug 12, 2026 | Management or board change | ASX |
|---|
| Change of Director Interest Notice - C Maley | Aug 12, 2026 | Management or board change | ASX |
|---|
| Becoming a substantial holder | Aug 11, 2026 | Ownership change notice | ASX |
|---|
| Successful Completion of $32 million Entitlement Offer | Aug 10, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - SPL | Aug 10, 2026 | Financing | ASX |
|---|
| Entitlement Offer Investor Presentation | Jul 14, 2026 | Offer document | ASX |
|---|
| Fully Underwritten Entitlement Offer to Raise $32 Million | Jul 14, 2026 | Financing | ASX |
|---|
| Quarterly Activities Report and Appendix 4C | Jul 14, 2026 | Quarterly report | ASX |
|---|
| DEP milestone triggers partner option fee | Jul 2, 2026 | Operations update | ASX |
|---|
| Positive DEP HER2-Lu preclinical data support Phase 1 entry | Jul 1, 2026 | Other filings | ASX |
|---|
| DEP radiopharmaceutical data supports patent application | Jul 1, 2026 | Other filings | ASX |
|---|
| FDA confirms path to DEP HER2 first-in-human study | Apr 21, 2026 | Other filings | ASX |
|---|
| Half Yearly Report and Accounts | Feb 17, 2026 | Interim report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 28, 2026 | Quarterly report | ASX |
|---|
| AGM Chair address and CEO presentation | Nov 14, 2025 | Meeting outcome | ASX |
|---|
| Upfront payment of USD $5.5 million received from Genentech | Oct 21, 2025 | Acquisition or disposal | ASX |
|---|
| SPL:Research & Option Agreement with Radiopharm Theranostics | Sep 30, 2025 | Other filings | ASX |
|---|
| Presentation to Accompany License Agreement with Genentech | Sep 21, 2025 | Operations update | ASX |
|---|
| Starpharma Announces License Agreement with Genentech | Sep 21, 2025 | Material contract | ASX |
|---|
| $3.7M R&D Tax Incentive Received | Aug 27, 2025 | Results | ASX |
|---|
| FY25 Key Financial Results and Annual Report | Aug 26, 2025 | Annual report | ASX |
|---|
| 2025 Appendix 4E Preliminary Financial Report | Aug 26, 2025 | Results | ASX |
|---|
| SPL receives positive FDA feedback on DEP SN38 for PROC | Dec 18, 2024 | Other filings | ASX |
|---|
| AGM Chair's address and CEO's presentation | Nov 26, 2024 | Meeting outcome | ASX |
|---|
| SPL7013 Nasal Spray Australia Update | Oct 17, 2024 | Other filings | ASX |
|---|
| Starpharma Receives $5.5M R&D Tax Incentive Refund | Sep 11, 2024 | Other filings | ASX |
|---|
| Annual Report to shareholders | Aug 21, 2024 | Annual report | ASX |
|---|
| Positive final DEP irinotecan Phase 2 clinical trial results | May 27, 2024 | Other filings | ASX |
|---|
| Starpharma Business Update | May 22, 2024 | Operations update | ASX |
|---|
| Starpharma and Medicxi Partnership Petalion Therapeutics | Apr 7, 2024 | Acquisition or disposal | ASX |
|---|
| S&P DJI Announces March 2024 Quarterly Rebalance | Mar 1, 2024 | Other filings | ASX |
|---|
| VivaGel BV US FDA Appeal Outcome | Feb 18, 2024 | Legal or regulatory action | ASX |
|---|
| Viraleze shows antiviral efficacy in COVID-19 patients | Jan 28, 2024 | Results | ASX |
|---|
| VivaGel BV sales and distribution agreement MENA region | Jan 22, 2024 | Operations update | ASX |
|---|
| Positive DEP docetaxel Phase 2 results | Dec 18, 2023 | Results | ASX |
|---|
| AGM Chairman's address and CEO presentation | Nov 29, 2023 | Other filings | ASX |
|---|
| Starpharma announces new CEO, Ms Cheryl Maley | Nov 9, 2023 | Management or board change | ASX |
|---|
| Starpharma receives $7.2 million R&D Tax Incentive refund | Oct 22, 2023 | Results | ASX |
|---|
| Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer | Oct 17, 2023 | Results | ASX |
|---|
| DEP irinotecan clinical data presented at AACR meeting | Oct 15, 2023 | Operations update | ASX |
|---|
| DEP irinotecan combination data presentation | Sep 26, 2023 | Operations update | ASX |
|---|
| VIRALEZ UK COVID-19 Clinical Study Completes Recruitment | Sep 25, 2023 | Operations update | ASX |
|---|
| Positive DEP irinotecan clinical results presentation | Sep 13, 2023 | Other filings | ASX |
|---|
| App 4E/Annual Report to shareholders | Aug 23, 2023 | Annual report | ASX |
|---|
| SPL to receive $6.5M from Mundipharma and VivaGel BV rights | Aug 13, 2023 | Other filings | ASX |
|---|
| Partnered Program Update | Jul 31, 2023 | Other filings | ASX |
|---|
| Trading Halt | Jul 28, 2023 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | Jul 28, 2023 | Trading halt or suspension | ASX |
|---|
| Starpharma partners with UQ to advance DEP radio pipeline | Jul 25, 2023 | Other filings | ASX |
|---|
| DEP HER2-radiodiagnostic shows imaging benefits | Jul 20, 2023 | Other filings | ASX |
|---|
| Clinical Trial Update | Jun 27, 2023 | Other filings | ASX |
|---|
| Starpharma CEO to retire in 2024 | Jun 8, 2023 | Other filings | ASX |
|---|
| VIRALEZE Nasal Spray Approved in Malaysia | Jun 5, 2023 | Other filings | ASX |
|---|
| HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model | Apr 26, 2023 | Other filings | ASX |
|---|
| Interim Report and Half-Year Financial Results | Feb 27, 2023 | Interim report | ASX |
|---|
| Quarterly Activities Report & Appendix 4C | Jan 29, 2023 | Quarterly report | ASX |
|---|
| Response to ASX Query Letters | Jan 12, 2023 | Explanation request | ASX |
|---|
| Starpharma receives $7.1M R&D tax incentive refund | Dec 22, 2022 | Other filings | ASX |
|---|
| VIRALEZE Nasal Spray Registered in Indonesia | Dec 14, 2022 | Other filings | ASX |
|---|
| Positive AZD0466 clinical data presented by AstraZeneca | Dec 13, 2022 | Other filings | ASX |
|---|
| AGM Chairman address and CEO presentation | Nov 29, 2022 | Other filings | ASX |
|---|
| VIRALEZE distribution agreement for Hong Kong and Macau | Oct 20, 2022 | Other filings | ASX |
|---|
| New clinical data for DEP cabazitaxel in prostate cancer | Sep 11, 2022 | Other filings | ASX |
|---|
| S&P DJI Announces September 2022 Quarterly Rebalance | Sep 2, 2022 | Other filings | ASX |
|---|
| Starpharma annual report and full year financial results | Aug 25, 2022 | Annual report | ASX |
|---|
| Starpharma signs new DEP agreement with MSD | Aug 10, 2022 | Other filings | ASX |
|---|
| VIRALEZE Protects Against Omicron in Viral Challenge Model | Jul 20, 2022 | Other filings | ASX |
|---|
| VIRALEZE relaunched by LloydsPharmacy in the UK | Jun 30, 2022 | Other filings | ASX |
|---|
| SPL signs expanded DEP research agreement with US Biopharma | Jun 26, 2022 | Other filings | ASX |
|---|
| SPL7013 in VIRALEZE virucidal against influenza A and B | May 17, 2022 | Other filings | ASX |
|---|
| Quarterly Cashflow and Activities Report | Apr 29, 2022 | Quarterly report | ASX |
|---|
| VIRALEZE to relaunch in the UK | Mar 31, 2022 | Other filings | ASX |
|---|
| SPL7013 in VIRALEZE virucidal against Omicron | Mar 1, 2022 | Other filings | ASX |
|---|
| VIRALEZE sales and distribution in Saudi Arabia and GCC | Feb 2, 2022 | Other filings | ASX |
|---|
| Starpharma receives $7.7M R&D tax incentive refund | Jan 19, 2022 | Other filings | ASX |
|---|
| VIRALEZE successfully launched in Vietnam | Dec 13, 2021 | Other filings | ASX |
|---|
| Starpharma signs DEP Research Agreement with US Biopharma Co | Dec 6, 2021 | Other filings | ASX |
|---|
| VIRALEZE distribution agreement and launch in Vietnam | Dec 2, 2021 | Other filings | ASX |
|---|
| VIRALEZE registered in Vietnam with launch this week | Nov 30, 2021 | Other filings | ASX |
|---|
| Positive DEP phase 2 interim results in prostate cancer | Nov 25, 2021 | Interim report | ASX |
|---|
| VIRALEZE distribution and supply to Vietnam | Oct 25, 2021 | Other filings | ASX |
|---|
| VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy | Oct 7, 2021 | Other filings | ASX |
|---|
| VIRALEZE Protects Against SARS-CoV-2 in Challenge Model | Aug 23, 2021 | Other filings | ASX |
|---|
| VIRALEZE well tolerated in multiple dose clinical study | Aug 17, 2021 | Other filings | ASX |
|---|
| VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant | Jul 27, 2021 | Other filings | ASX |
|---|
| VIRALEZE UK Update | Jun 20, 2021 | Other filings | ASX |
|---|
| VIRALEZE SPL7013 virucidal against multiple COVID variants | Jun 17, 2021 | Other filings | ASX |
|---|
| VIRALEZE antiviral nasal spray registered for sale in India | Jun 11, 2021 | Other filings | ASX |
|---|
| VIRALEZE SPL7013 highly active in UK variant of coronavirus | Jun 1, 2021 | Other filings | ASX |
|---|
| VIRALEZE launches in Europe | May 6, 2021 | Other filings | ASX |
|---|
| VIRALEZE to be launched with LloydsPharmacy in the UK | Mar 24, 2021 | Other filings | ASX |
|---|
| DEP HER2-lutetium outperforms in human breast cancer model | Mar 15, 2021 | Other filings | ASX |
|---|
| VIRALEZE antiviral nasal spray registered in Europe | Feb 22, 2021 | Other filings | ASX |
|---|
| Starpharma signs DEP ADC Research Agreement with MSD | Feb 11, 2021 | Other filings | ASX |
|---|
| AZD0466 clinical DEP program global expansion | Feb 8, 2021 | Other filings | ASX |
|---|
| VIRALEZE COVID-19 nasal spray study to commence in January | Dec 22, 2020 | Other filings | ASX |
|---|
| VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21 | Dec 9, 2020 | Other filings | ASX |
|---|
| SPL7013 shows potent antiviral activity in RSV | Nov 18, 2020 | Other filings | ASX |
|---|
| Completion of Placement and SPP raises $48.9M in total | Oct 29, 2020 | Financing | ASX |
|---|
| Starpharma receives $5.7M R&D tax incentive refund | Oct 20, 2020 | Other filings | ASX |
|---|
| Share Purchase Plan offer document | Oct 6, 2020 | Financing | ASX |
|---|
| Starpharma completes oversubscribed A$45M placement | Sep 30, 2020 | Financing | ASX |
|---|
| SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2 | Sep 14, 2020 | Other filings | ASX |
|---|
| Starpharma awarded $1M MRFF funding for COVID-19 spray | Sep 2, 2020 | Other filings | ASX |
|---|
| SPL creates slow release soluble DEP remdesivir nanoparticle | Aug 31, 2020 | Other filings | ASX |
|---|
| SPL7013 nasal spray for COVID19 development update | Aug 25, 2020 | Other filings | ASX |
|---|
| Starpharma signs new DEP partnership with Chase Sun | Aug 16, 2020 | Other filings | ASX |
|---|
| DEP irinotecan boosts immuno-oncology in colon cancer models | Jun 28, 2020 | Other filings | ASX |
|---|
| DEP products showcased at AACR 2020 | Jun 22, 2020 | Other filings | ASX |
|---|
| DEP lutetium effective in human prostate cancer model | Jun 17, 2020 | Other filings | ASX |
|---|
| VivaGel BV launched in central and eastern Europe | Jun 16, 2020 | Other filings | ASX |
|---|
| DEP irinotecan phase 2 commences after positive phase 1 | May 7, 2020 | Other filings | ASX |
|---|
| SPL7013 shows significant activity against coronavirus | Apr 15, 2020 | Other filings | ASX |
|---|
| Quarterly Cashflow and Activity Report | Apr 7, 2020 | Quarterly report | ASX |
|---|
| Okamoto licenses VivaGel antiviral condom in Asian countries | Mar 3, 2020 | Other filings | ASX |
|---|
| VivaGel BV launched in Asia | Feb 12, 2020 | Other filings | ASX |
|---|
| Starpharma receives US$3M milestone from AstraZeneca | Feb 10, 2020 | Other filings | ASX |
|---|
| Quarterly Cashflow Report | Jan 28, 2020 | Quarterly report | ASX |
|---|
| Commencement of phase 1 trial for AZD0466 utilising DEP | Dec 29, 2019 | Other filings | ASX |
|---|
| Starpharma receives $4.9M R&D tax incentive refund | Dec 15, 2019 | Other filings | ASX |
|---|
| DEP cabazitaxel progresses to phase 2 on positive results | Dec 9, 2019 | Other filings | ASX |
|---|
| AGM - Chairman address and CEO presentation | Nov 21, 2019 | Other filings | ASX |
|---|
| VivaGel condom receives regulatory approval in Europe | Nov 20, 2019 | Other filings | ASX |
|---|
| UK launch of VivaGel BV | Nov 12, 2019 | Other filings | ASX |
|---|
| DEP outperforms Gemzar in human pancreatic cancer model | Oct 30, 2019 | Other filings | ASX |
|---|
| FDA Authorises Clinical Trial with AstraZeneca DEP product | Sep 25, 2019 | Other filings | ASX |
|---|
| DEP irinotecan synergistic with Lynparza in refractory model | Sep 12, 2019 | Other filings | ASX |
|---|
| VivaGel BV regulatory approvals continue in Asia | Sep 2, 2019 | Other filings | ASX |
|---|
| Positive results with Targeted DEP using antibody fragment | Aug 29, 2019 | Other filings | ASX |
|---|
| Promising efficacy signals observed in ongoing DEP trials | Aug 27, 2019 | Other filings | ASX |
|---|
| First Asian Regulatory Approvals Received for VivaGel BV | Aug 14, 2019 | Other filings | ASX |
|---|
| Starpharma commences phase 1/2 DEP irinotecan trial | Aug 7, 2019 | Other filings | ASX |
|---|
| VivaGel BV launched in Europe | Jun 27, 2019 | Other filings | ASX |
|---|
| Starpharma signs second oncology agreement with AstraZeneca | Jun 2, 2019 | Other filings | ASX |
|---|
| DEP irinotecan combination outperforms in colon cancel model | May 24, 2019 | Other filings | ASX |
|---|
| First VivaGel BV launch globally in Australia by Aspen | Apr 16, 2019 | Other filings | ASX |
|---|
| Starpharma receives $4.0M R&D tax incentive refund | Mar 11, 2019 | Other filings | ASX |
|---|
| Interim Report and Half-Yearly Financial Results | Feb 26, 2019 | Interim report | ASX |
|---|
| Response to ASX Aware Letter | Jan 7, 2019 | Explanation request | ASX |
|---|
| VivaGel condom receives final regulatory approval in Japan | Jan 1, 2019 | Other filings | ASX |
|---|
| US FDA requests further data for VivaGel BV approval | Dec 27, 2018 | Other filings | ASX |
|---|
| US VivaGel BV licensed for A$142M milestones plus royalties | Dec 19, 2018 | Other filings | ASX |
|---|
| DEP products outperform in human pancreatic cancer model | Nov 16, 2018 | Other filings | ASX |
|---|
| Starpharma Investor Presentation for Citi Conference | Oct 16, 2018 | Other filings | ASX |
|---|
| DEP irinotecan outperforms in pancreatic cancer model | Sep 5, 2018 | Other filings | ASX |
|---|
| AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy | Aug 31, 2018 | Other filings | ASX |
|---|
| Annual report and full year financial results | Aug 21, 2018 | Annual report | ASX |
|---|
| VivaGel BV NDA advances to next stage of FDA review | Jul 9, 2018 | Other filings | ASX |
|---|
| Starpharma licenses VivaGel BV to Mundipharma for Europe | Jun 26, 2018 | Other filings | ASX |
|---|
| Mundipharma licenses Starpharmas VivaGel BV | May 3, 2018 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly Cashflow Report | Apr 30, 2018 | Quarterly report | ASX |
|---|
| Starpharma completes US New Drug Application for VivaGel BV | Apr 29, 2018 | Other filings | ASX |
|---|
| Starpharma receives $3.7M R&D tax incentive refund | Feb 21, 2018 | Other filings | ASX |
|---|
| Starpharma to commence DEP cabazitaxel phase 1/2 trial | Jan 31, 2018 | Other filings | ASX |
|---|
| VivaGel BV treatment clinical submission under rolling NDA | Dec 20, 2017 | Other filings | ASX |
|---|
| NDA submission for VivaGel BV in the US | Nov 21, 2017 | Other filings | ASX |
|---|
| VivaGel BV granted marketing approval in Australia | Oct 24, 2017 | Other filings | ASX |
|---|
| Starpharma and Peter Mac Cancer Centre awarded DEP Grant | Oct 9, 2017 | Other filings | ASX |
|---|
| AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor | Sep 28, 2017 | Other filings | ASX |
|---|
| DEP docetaxel positive phase 1 results, phase 2 commences | Sep 22, 2017 | Other filings | ASX |
|---|
| Starpharma and Monash awarded STEM Business Fellowships | Aug 9, 2017 | Other filings | ASX |
|---|
| Successful VivaGel Phase 3 results and NDA planned for rBV | Aug 6, 2017 | Other filings | ASX |
|---|
| VivaGel BV phase 3 results timing and commercialisation | Jul 4, 2017 | Other filings | ASX |
|---|
This page holds 200 of 298 filings.